Kornimate/medical-research-clean huggingface dataset:
rosiglitazone in the treatment of hiv-associated hyperlipidemia

Conditions: HIV Infections; Hyperlipidemia

Summary: the purpose of this research is to study the effects of rosiglitazone, a drug usually taken for type ii diabetes, on hiv-associated hyperlipidemia. hiv-associated lipodystrophy is a medical condition characterized by gradual changes in the distribution of body fat. the body fat located in the extremities and face disappears while body fat around the abdomen and upper back increases. certain biochemical changes occur in association with these changes in fat distribution. lipid levels particularly serum triglycerides are increased. hdl, the "good cholesterol" is decreased. higher than normal level of insulin or insulin resistance is also found in this condition. this latter condition is one of the hallmarks of type ii diabetes. the protease inhibitors, a class of hiv medications, are associated with the occurrence of hiv-associated lipodystrophy. it has been suggested that a biochemical pathway known as the peripheral peroxisomal activating receptor (ppar) gamma system is blocked leading to the onset of this condition. rosiglitazone is a new drug approved by the fda in 1999 for the treatment of type ii diabetes. it lowers blood sugar by improving insulin resistance, which as mentioned before, is the hallmark of type ii diabetes. it has also been noted to improve blood lipid levels. rosiglitazone works by stimulating the ppar gamma system. it is hoped that this drug can turn on the ppar system and reverse the hiv-associated lipodystrophy syndrome.


Eligibility criteria:
inclusion criteria: * hiv-positive with cd4 count \> 500 and undetectable viral load * treated with protease inhibitors for more than three months * serum triglycerides \> 400mg/dl * clinical diagnosis of hiv-associated lipodystrophy * no history of type ii diabetes * fasting blood sugar \< 126 mg/dl * no history of liver disease * negative hepatitis b antigen and hepatitis c antibody * not on the following medications: warfarin, digoxin, nifedipine, erythromycin, cyclosporine or hmg coa-reductase inhibitors * hemoglobin \> 11g/dl * women of childbearing age must consent to barrier contraception

Keywords: hiv-associated hyperlipidemia
clinical study on the effect of tizanidine on the function and pain of patients after shoulder arthroscopy

Conditions: Rotator Cuff Tears

Summary: the perspective, randomized controlled trial is to investigate and evaluate the effect of tizanidine on the function and pain of patients with rotator cuff tear after shoulder arthroscopy;


Eligibility criteria:
inclusion criteria: 1 patients who were diagnosed as supraspinatus tendon and infraspinatus tendon tear and underwent shoulder arthroscopic surgery in the second affiliated hospital of zhejiang university; 2 age 20\~70 years old; 3 those with a long medical history, and symptoms such as shoulder joint pain and weakness in a short period of time are obviously aggravated; 4. after 3 months of medication and physical therapy, the symptoms and functions have not improved significantly; 5 volunteer to participate in this study, and the person and his/her family members have given informed consent to the content of this study and signed the consent form exclusion criteria: 1. patients with simple frozen shoulder; 2. patients with shoulder joint tuberculosis, gout, tumor, rheumatoid disease or infectious disease; 3. there are other joint pain factors before operation; 4 patients with subscapularis tendon tear, long head tendinopathy requiring surgical treatment, and severe shoulder synovitis were found during the operation; 5 patients with upper limb nerve injury, shoulder fracture, bone defect or severe osteoporosis; 6. patients with serious organ or hematopoietic system and other primary diseases; 7. those who are allergic to the drugs used in this study; 8 women who are breast-feeding, pregnant or preparing to become pregnant; 9 patients with language and communication disorders, mental history, cognitive dysfunction, etc. who cannot cooperate with the completion of nursing intervention and research, and cannot complete the questionnaire required for this study.
fremanezumab compassionate use program for pediatric patients

Conditions: Migraine

Summary: this is a compassionate use program (cup) based on a licensed physician's unsolicited request. specifically, this cup is for male and female pediatric patients 6 to 17 years with a diagnosis of either episodic or chronic migraine who have successfully completed the teva sponsored study tv48125-cns-30084 (space study).

patients must have successfully completed the clinical trial according to the 30084 protocol, without any major protocol violations or tolerability issues, or who are anticipated to complete this trial within the next 2months, and whose requesting/treating physician is requesting continued supply of the investigational medicinal product (imp) known as tev-48125 (fremanezumab) on behalf of the patient.

Eligibility criteria:
inclusion criteria: * eligible patients may enter this cup after successfully completing tv48125-cns-30084 and all end of study procedures * in the opinion of your physician/investigator are able to continue imp (fremanezumab) in a safe and compliant way. exclusion criteria: * additional criteria may apply, please contact your physician/investigator for more information.
oral direct factor xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis - the einstein dvt study

Conditions: Venous Thrombosis

Summary: this is a multicenter, randomized, open-label, assessor-blind, event-driven, non-inferiority program for efficacy with a study treatment duration of 3, 6 or 12 months in patients with confirmed acute symptomatic dvt without symptomatic pe (einstein-dvt).

within the us 'johnson \& johnson pharmaceutical research \& development, l.l.c.' is sponsor. the treatment period was followed by an observational period of 30 days starting the day after the last intake of study medication, regardless of the actual duration of study drug administration. participants who did not complete the treatment period also entered the observational period. it was also possible that participants did not enter the observational period, e.g. due to withdrawal of consent or termination of study participation. participants who were transferring from study 11702 dvt (nct00440193) to the extension study 11899 (nct00439725) did not enter the observational period.

Eligibility criteria:
inclusion criteria: * confirmed acute symptomatic proximal dvt without symptomatic pe exclusion criteria: * legal lower age limitations (country specific) * thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of dvt and/or pe * other indication for vka than dvt and/or pe * the pre-randomization anti-coagulant treatment (criteria # 4) has been prolonged from 36 hours to a maximum of 48 hours.
the impact of covid-19 pandemic on colorectal cancer prevention due to delays in diagnosis: a global study

Conditions: Colorectal Cancer

Summary: screening programs have been associated with a substantial reduction in colorectal cancer (crc) mortality through endoscopic resection of preneoplastic lesions and detection of early-stage invasive cancers. in march 2020, the world health organization declared as a pandemic the outbreak of coronavirus disease 2019 (covid-19), caused by sars-cov-2. since then, the sars-cov-2 have never stopped spreading, causing an unprecedented situation with highly restrictive considerations to be adopted by the majority of countries worldwide. health-care facilities have been making an enormous effort to assist patients affected by covid-19, while adopting measures to maintain a safe environment for patients and healthcare professionals. as a result, the usual workflow in endoscopy departments changed dramatically, leading to an increase in cancelled procedures, probably increasing the future burden of colorectal cancer due to delays in diagnosis.


Eligibility criteria:
* patients who underwent colonoscopy between the 1st october 2020 and the 31st december 2020 (pandemic cohort) * patients who underwent colonoscopy between the 1st october 2019 and the 31st december 2019 (pre-pandemic cohort)
clinical and laboratory characteristics of patients admitted with syncope; diagnosis and follow up after these patients

Conditions: Diagnosis; Recurrence

Summary: the investigators hypothesis is that a significant number of patients may remain without specific cause and have recurrent syncope with its associated physical and mental morbidity.

1. patients with diagnosis of syncope who were admitted to the medical ward will be interviewed and their charts reviewed to rule in or out the diagnosis of syncope. 2. assess physical and mental injury as a result of syncope. 3. the lab workup will be documented including; 1. - routine blood tests. * troponin level. 2. - ecg. * echocardiogram * brain ct. * eeg. * u/s doppler of carotids. * tilt tests. 4. at the time of diagnosis the final diagnosis will be documented including recommendations for patients to prevent syncope after discharge. 5. follow up after patients by phone verifying recurrence of syncope and resulting physical and or mental injury if any.

Eligibility criteria:
inclusion criteria: * patients with diagnosis of syncope on admission to the medical ward. exclusion criteria: * patients with loss of consciousness due to other than low perfusion of the brain * patients that can't sign a consent form * patients that we can't get details about the episode of the syncope

Keywords: syncope evaluation recurrence morbidity
dki combined with apt for post-treatment assessment of ovarian malignancies and correlation with xrcc2 gene

Conditions: Malignant Tumor of the Ovary; XRCC2 Gene Mutation

Summary: ovarian cancer is one of the common causes of cancer death in women worldwide. despite the continuous development of diagnostic and treatment techniques, the survival rate of ovarian cancer patients has not improved significantly, and the important reason for the high mortality rate and poor prognosis is the lack of effective means to assess the effectiveness of treatment. the methods to monitor the effectiveness of ovarian cancer treatment and dynamic risk stratification by conventional imaging or single tumour marker levels are rather limited. in recent years, dki and apt imaging have made some achievements in evaluating the post-treatment outcome of tumours, and the quantitative parameters of dki combined with apt as a non-invasive biological marker are expected to be an effective way to address the limitations of assessing the treatment outcome by non-invasively detecting the changes in the signal of water protons and the diffusion information of non-normally distributed water molecules in the tumour tissue to observe the changes of protein and microstructure in the tumour cells. this project aims to collect patients who have come to our hospital for treatment. this project aims to collect patients with ovarian malignancies who come to our hospital and perform dki, apt sequence and xrcc2 gene examination before and after treatment, and to statistically analyse the obtained parameters to assess the value of dki combined with apt in monitoring the treatment effect of ovarian malignancies and the correlation with xrcc2 gene. this will help to promote individualised and precise treatment of ovarian cancer and improve prognosis.


Eligibility criteria:
inclusion criteria: no previous history of ovarian tumours or ovarian surgery; no concurrent other tumours, no history of oncology or treatment such as radiotherapy or chemotherapy; confirmed by pathological histology; receiving chemotherapy with a combination of platinum and purple shirt for at least 3 cycles; no contraindications to mri exclusion criteria: recurrent ovarian malignancy; too old, poor physical infrastructure; severe medical comorbidity; incomplete patient data collection; lost to follow-up
integrative health interventions in symptom management of pediatric patients

Conditions: Cancer; Pediatric Cancer

Summary: as healthcare demands high-quality cost-effective care and patients seek self-management strategies, integrative medicine has become more of an interest to patients, physicians, and administrators. the nih has a dedicated center (national center for complementary and integrative health) for integrative therapies. additionally, these treatments must meet evidence-based criteria for efficacy to be considered for reimbursement and in order for clinical settings to integrate them into the standard of care.

the care of children at the quaternary children's hospital is focused in traditional western medicine modalities of diagnosis, surgery, and medical treatment with pharmacologic medications. however, integrative health modalities, such as acupuncture, massage, reiki, nutritional supplements, or oral complementary therapies (such as cannabinoids) have been increasingly discussed by our patients, especially during palliative care consults. as healthcare demands high-quality cost-effective care and patients seek self-management strategies, integrative medicine has become more of an interest to patients, physicians, and administrators. the nih has a dedicated center (national center for complementary and integrative health) for integrative therapies. additionally, these treatments must meet evidence-based criteria for efficacy to be considered for reimbursement and in order for clinical settings to integrate them into the standard of care. the objective of this project is to examine feasibility, timing, appropriate measures, and provide the basis for future in-depth study of the outcomes of individual integrative symptom management strategies. hypotheses: children, adolescents, and young adults will be able to complete electronic self-report questionnaires and physical measures before and after integrative interventions, and monthly. caregivers will be able to complete electronic proxy questionnaires before and after integrative interventions, and monthly. integrative interventions will be associated with changes on the questionnaires and physical measures such as a decrease in frequency, severity, or level of interference with symptoms. participants will rate their satisfaction with integrative interventions positively.

Eligibility criteria:
inclusion criteria: * any chco patient referred for integrative interventions by the pain service or the palliative care service exclusion criteria: * patients who have non-consenting providers or caregivers * any patient the medical team feels is inappropriate for the study
compliance of parents of children with cerebral palsy to home program questionnaire

Conditions: Cerebral Palsy

Summary: this study aims to evaluate the psychometric properties of the compliance of parents of children with cerebral palsy to home program assesment questionnaire (cphp-q), a caregiver-report for adherence and frequency of home program implementation of parents of children with cerebral palsy.


Eligibility criteria:
inclusion criteria: 1. having a child with cp 2 to 18 years, 2. being a primary caregiver, 3. understanding of turkish without an interpreter, and turkish literacy, exclusion criteria: 1. having any chronic illness or disability to prevent the home program, 2. haven't applied home program before.

Keywords: home program cerebral palsy questionnaire development parent
therapeutic effects of the processing of positive memories technique on posttrauma health

Conditions: Post-Traumatic Stress Disorder

Summary: the current study will examine daily-level impacts of a technique addressing positive memory retrieval on thoughts, feelings, and health among individuals with trauma experiences.

post-traumatic stress disorder (ptsd) is primarily a memory encoding- and retrieval-based disorder. if untreated, there are significant physical, psychological, social, and economic impacts for an individual, their families, and the society broadly. research demonstrates that positive memory processes contribute to the etiology and maintenance of ptsd symptoms. indeed, difficulties in retrieving and discussing positive memories are amplified among individuals with ptsd. further, interventions capitalizing on (positive) memory retrieval have been linked to enhanced psychological well-being. considering this literature, the processing of positive memories technique (ppmt) was developed as a promising new treatment approach for posttraumatic stress disorder (ptsd), which involves detailed narration and processing of specific positive autobiographical memories. this study uses an innovative research protocol that combines case-series design and daily diary approaches to the effects of ppmt on daily affect, daily cognitions, and daily ptsd symptoms. it is hypothesized that at the daily level, in comparison to their an individual's pre-ppmt levels, following the ppmt intervention, participants will report (1) a lower count of endorsed daily ptsd symptoms, (2) increases in daily positive affect and decreases in daily negative affect, (3) increases in positive affect reactivity to daily positive events, and (4) decreases in daily posttrauma cognitions.

Eligibility criteria:
inclusion criteria: * being aged between 18 and 65 years * endorsing a trauma with posttrauma symptoms * access to an electronic device with internet capabilities * working knowledge of english * being a current resident of the dallas fort worth metroplex * willingness and availability to participate in approximately 10 weeks of this study (including 4 therapy sessions) * willingness to be video-recorded during sessions for quality control purposes exclusion criteria: * active suicidal plan, suicidal attempt, homicidal plan, or homicidal attempt (past 3 months including current) * currently in therapy with a mental health provider

Keywords: posttrauma health positive autobiographical memories trauma
acceptance-based treatment for prostate cancer distress

Conditions: Early Stage Prostate Cancer

Summary: prostate cancer (pca) is the most common type of cancer in men and the second leading cause of death in american men. those diagnosed with localized prostate cancer encounter three sources of psychological distress: 1) diagnosis itself, 2) treatment decision making, and 3) the often life-altering side effects of treatment. in addition, patients who choose to undergo active surveillance which focuses on monitoring cancer in lieu of treatment, experience distress related to living with cancer. acceptance and commitment therapy (act) is an established psychosocial intervention that has been used extensively for mental health treatment and has shown benefits for various chronic conditions. act is a behavioral intervention that focuses on tolerating distress and improving function. this pilot study is designed to test the feasibility of act for distress reduction and improved quality of life in patients recently diagnosed with early-stage, localized pca.


Eligibility criteria:
inclusion criteria: * localized prostate cancer in stages i or ii * ability to give informed consent * age 18 to 80 years old * willingness to come in for a day long intervention exclusion criteria: * acute psychosis * suicidal ideation * homicidal ideation * active substance abuse * dementia

Keywords: prostate cancer behavioral acceptance and commitment therapy distress
de-escalated conformal radiation expedited sequentially with chemotherapy for endometrial cancer

Conditions: Endometrial Cancer

Summary: the goal of this study is to evaluate short course radiation in the post-operative female pelvis after hysterectomy in stage iii-iva endometrial adenocarcinoma patients, or any stage patients with uterine serous or carcinosarcoma histology. the investigators hypothesize that short course pelvic radiation will have an acute and late grade 3-4 toxicity rate \< 10%, and patients will benefit from both convenient and effective loco-regional control comparable to the traditional 5-6 weeks of radiation.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed stage iiia-iva endometrial cancer, or any stage i-iva where any proportion of the tumor is uterine serous, clear cell, de-differentiated, or carcinosarcoma histology. * must have already undergone radical hysterectomy. hysterectomy may have occurred no more than one year prior to enrollment. * at least 18 years of age. * ecog performance status ≤ 2 * minimal bone marrow and organ function as defined below: * leukocytes ≥ 1,000 cumm * absolute neutrophil count ≥ 500 cumm * platelets ≥ 50,000 cumm * hemoglobin ≥ 7g/dl * ability to understand and willingness to sign an irb approved written informed consent document (or that of legally authorized representative, if applicable). exclusion criteria: * prior radiation to the pelvis. * currently receiving any investigational agents. * uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, inflammatory bowel disease, or irritable bowel disease. * patients with hiv are eligible unless their cd4+ t-cell counts are \< 350 cells/mcl or they have a history of aids-defining opportunistic infection within the 12 months prior to registration. concurrent treatment with effective art according to dhhs treatment guidelines is recommended.
role of pet/mri in head and neck cancer

Conditions: Head and Neck Cancer; Benign Neoplasm; Malignant Neoplasm

Summary: study aim was to investigate the diagnostic role of positron emission tomography / magnetic resonance imaging (pet/mri) in head and neck cancer.

this study was assessed the role of diffusion weighted imaging (dwi) in discriminating between benign and malignant lesions in head and neck cancer as well as studying the relationship between glucose metabolism (18f-fdg) and apparent diffusion coefficient (adc) for better tumor assessment.

Eligibility criteria:
inclusion criteria: * proved head and neck cancer * underwent pet/ct and pet/mri * lymph nodes due to primary head and neck cancer. for healthy subject: * no previous history of malignancy. * no inflammation or infection in the neck region. * lymph node size \<10mm. exclusion criteria: * patients treated before by radiotherapy / chemoradiotherapy * patients underwent surgery * artifacts